- Conditions
- Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
- Interventions
- Pioglitazone, Placebo
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 170
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2605541, Insulin glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 33
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Concord, California + 30 more
- Conditions
- Type 2 Diabetes, Diabetic Kidney Disease
- Interventions
- SGLT2 inhibitor
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo-matching dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 2,996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 164
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
- Interventions
- Technosphere® Insulin, Usual Care
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 12
- States / cities
- Mission Hills, California • San Diego, California • Palm Harbor, Florida + 8 more
- Conditions
- Type 2 Diabetes
- Interventions
- Exenatide, Glargine, Rapid-acting insulin analogs
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2605541, Human Insulin NPH, Oral Antihyperglycemic Medications (OAM)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 641 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 20
- States / cities
- Tempe, Arizona • Concord, California • Fresno, California + 17 more
- Conditions
- Type 2 Diabetes
- Interventions
- Lispro mix 75/25, Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Diabetes Mellitus
- Interventions
- Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
- Drug · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Psoriatic Arthritis (PsA)
- Interventions
- GLP-1 agonists, Nutrition Counseling
- Drug · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Cardiovascular Events, Type2 Diabetes, Renal Disease
- Interventions
- SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 781,430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin detemir, insulin NPH
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 503 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 26 more
- Conditions
- Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
- Interventions
- Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide)
- Drug
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- INT131 besylate, Pioglitazone HCl, Placebo
- Drug
- Lead sponsor
- InteKrin Therapeutics, Inc.
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 59
- States / cities
- Carmichael, California • Los Angeles, California • San Diego, California + 48 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- linagliptine 5 mg, linagliptine 5 mg and pioglitazone 30 mg
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 82 Years
- Enrollment
- 2,122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 13
- States / cities
- Chula Vista, California • Spring Valley, California • Walnut Creek, California + 10 more
- Conditions
- Type 2 Diabetes
- Interventions
- Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs
- Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- New York, New York • Charlottesville, Virginia
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec, Metformin, SGLT2 inhibitor
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 933 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 32
- States / cities
- Fresno, California • La Mesa, California • Lancaster, California + 26 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs)
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 571 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 50
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Huntington Park, California + 42 more
- Conditions
- Diabetes
- Interventions
- Liraglutide, DPP-4 inhibitor
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 50 Years to 120 Years
- Enrollment
- 168,690 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type II Diabetes, Cardiovascular Disease
- Interventions
- Intensive discharge intervention
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertension, Diabetes Mellitus, Type 2
- Interventions
- Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
- Drug · Device · Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 35 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Type II Diabetes, Nonalcoholic Fatty Liver
- Interventions
- DPP4 inhibitor, Pioglitazone, Lantus insulin
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Hyperglycemia, Cancer
- Interventions
- Diabetes, Control Group
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Coronado, California + 54 more